Enlivex: Positive Results in Trial for Treatment of Bone Marrow Transplant Recipients

Israeli company Enlivex reports a successful trial on its treatment for bone marrow transplant recipients. According to the company, as many as 70 percent of transplant recipients develop a condition known as Graft-versus-Host Disease, which causes severe health problems, and has no effective treatment.